NASDAQ:LEXX • US52886N4060
ChartMill assigns a Buy % Consensus number of 83% to LEXX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-10 | HC Wainwright & Co. | Initiate | Buy |
| 2024-03-05 | Maxim Group | Maintains | Buy -> Buy |
| 2023-07-21 | Maxim Group | Initiate | Buy |
7 analysts have analysed LEXX and the average price target is 4.59 USD. This implies a price increase of 639.96% is expected in the next year compared to the current price of 0.6203.
The consensus rating for LEXARIA BIOSCIENCE CORP (LEXX) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering LEXARIA BIOSCIENCE CORP (LEXX) is 7.